78 results
Page 3 of 4
S-3
kzt9n173 nx
5 Apr 22
Shelf registration
4:28pm
8-K
EX-99.1
xflxvadgu3 mk1ip7
5 Apr 22
Longeveron Expands Executive Leadership Team; Appoints
4:01pm
8-K
EX-99.1
ipw1l4d0cdj2
11 Mar 22
Longeveron Announces Fourth Quarter and Full Year 2021 Financial Results and Operational Progress
8:45am
8-K
EX-99.1
ykh7vxkkm2ef9z6p
17 Feb 22
Longeveron Adds Seasoned Biotech Executive Todd Girolamo to Its Board of Directors
4:02pm
8-K
EX-99.1
mb9oat
10 Jan 22
Regulation FD Disclosure
10:38am
424B3
w4i d4dvgsm
22 Dec 21
Prospectus supplement
5:07pm
8-K
EX-99.1
s6f5iwkkzqw6xu7
7 Dec 21
Regulation FD Disclosure
4:51pm
8-K
EX-99.1
oe8m2c1ou7 tihw2c
3 Dec 21
Longeveron Inc. Announces Pricing of a $20.5 Million Private Placement
5:13pm
8-K
EX-99.2
pp1zi fv0hkw4pz
3 Dec 21
Longeveron Inc. Announces Pricing of a $20.5 Million Private Placement
5:13pm
8-K
EX-99.1
4bdupz9 go0xrv
18 Nov 21
U.S. Food and Drug Administration Approves Longeveron’s Lomecel-B for Rare Pediatric Disease Designation to Treat
4:58pm
8-K
EX-99.1
tmnayrzb2modv08g79l
12 Nov 21
Longeveron Inc. Provides Corporate Update and Reports Third Quarter 2021 Financial Results
8:00am
8-K
EX-99.1
k6e15 4eebkniux
1 Oct 21
Regulation FD Disclosure
4:02pm
8-K
EX-99.2
bymfyov
1 Oct 21
Regulation FD Disclosure
4:02pm
8-K
EX-99.1
wafnanwswi4e
9 Sep 21
Regulation FD Disclosure
9:28am
8-K
EX-99.1
krmymt
13 Aug 21
Longeveron Announces Topline Results of Phase 2b Study of Lomecel-B for Aging Frailty
1:46pm
8-K
EX-99.1
ic0mpybc yah4v6j
13 Aug 21
Longeveron Inc. Provides Corporate Update and Reports Second Quarter 2021 Financial Results
10:32am